Arthritis drug might reduce COVID-19 deaths: trial
Tocilizumab appears to benefit patients who are severe enough to be hospitalised, study shows
Tocilizumab cuts the risk of death among patients hospitalised with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, according to trial results that await peer-review.
The findings — from the RECOVERY trial, which has been testing a range of potential treatments for COVID-19 since March 2020 — should help clear up confusion about whether tocilizumab has any benefit for COVID-19 patients after a slew of recent mixed trial results.
